Guide | 10 July, 2018 | Download PDF

Medicines are crucial for improving our health and well-being. But in the European Union (EU), the price of new patented medicines is growing higher every year, jeopardising the ability of patients to access them when needed and threatening the sustainability of our healthcare systems. At the same time, research shows that most new medicines that are brought to market offer little, or no, added therapeutic value over those that are already available. In addition, the increasing push to accelerate market approval involves evaluating medicines on the basis of limited clinical data. This leads to greater uncertainty about a therapy’s true effects.

HAI’s EU Projects team focuses on three core areas of medicines policy to improve public health outcomes in the EU.

This guide explains our work in these areas.

Download the guide